Johnson & Johnson's (JNJ) Q4 earnings and revenue estimates were nudged higher before results on Wednesday, BofA Securities said Friday in a report.
The firm's estimate for per-share earnings rose to $2.08 from $2.03 with revenue forecast at $22.61 billion, up from $22.52 billion, the report said.
In 2025 and 2026, BofA said estimates are "slightly lower" with sales in the medical technology segment seen easing, and underlying EPS estimates are down on "lower revenues, higher currency headwinds, and tax."
BofA said the focus of the Q4 earnings call will likely include an indication of the impact of the acquisition of Intra-Cellular Therapies (ITCI), along with currency fluctuations seen as a "material headwind to reported sales and EPS."
BofA cut the price target on Johnson & Johnson to $160 from $166 and reiterated its neutral rating.
Price: 147.24, Change: -0.53, Percent Change: -0.36
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.